BeiGene announces shareholder approval of charter amendments and faces patent infringement lawsuit over BRUKINSA

On June 15, 2023, at the 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) of BeiGene, Ltd. (the “Company”), the Company’s shareholders approved the Seventh Amended and Restated Memorandum and Articles of Association of the Company (the “Seventh Restated Articles”), which amended the Sixth Amended and Restated Memorandum and Articles of Association of the Company (the “Existing Articles”) to comply with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong (the “HK Listing Rules”).

(6) Ordinary resolution: within the parameters of the HK Listing Rules, to approve the granting of a share issue mandate to the Board of Directors to issue, allot or deal with (i) unissued ordinary shares (excluding our RMB Shares) and/or ADSs not exceeding 20% of the total number of issued ordinary shares (excluding RMB shares) of the Company and/or (ii) unissued RMB shares not exceeding 20% of the total number of issued RMB shares of the Company, each as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, subject to the conditions described in the Proxy Statement (the “General Mandate to Issue Shares”): Votes For Votes Against Abstentions Broker Non- Votes 840,972,117 211,977,909 51,762 — Accordingly, the General Mandate to Issue Shares was approved.

(5) Ordinary resolution: to authorize the Board of Directors to fix the auditors’ remuneration for the fiscal year ending December 31, 2023: Votes For Votes Against Abstentions Broker Non- Votes 1,052,931,046 57,900 12,842 — Accordingly, the Board of Directors was authorized to fix the auditors’ remuneration for the fiscal year ending December 31, 2023.

(7) Ordinary resolution: within the parameters of the HK Listing Rules, to approve the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding RMB shares) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares) of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, subject to the conditions described in the Proxy Statement (the “General Mandate to Repurchase Shares”): Votes For Votes Against Abstentions Broker Non- Votes 1,051,315,803 1,653,723 32,262 — Accordingly, the General Mandate to Repurchase Shares was approved.

(1) Ordinary resolution: to re-elect Dr. Margaret Dugan to serve as a Class I director until the 2026 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal: Votes For Votes Against Abstentions Broker Non-Votes 1,043,071,109 9,915,997 14,682 — Accordingly, Dr. Margaret Dugan was re-elected to serve as a Class I director.

(2) Ordinary resolution: to re-elect John V. Oyler to serve as a Class I director until the 2026 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal: Votes For Votes Against Abstentions Broker Non- Votes 1,040,325,525 12,461,780 214,483 — Accordingly, John V. Oyler was re-elected to serve as a Class I director.

(4) Ordinary resolution: to approve and ratify the selection of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company’s reporting accounting firms for the fiscal year ending December 31, 2023: Votes For Votes Against Abstentions Broker Non- Votes 1,052,805,024 172,917 23,847 — Accordingly, the selection of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company’s reporting accounting firms was approved and ratified.

(3) Ordinary resolution: to re-elect Dr. Alessandro Riva to serve as a Class I director until the 2026 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal: Votes For Votes Against Abstentions Broker Non- Votes 1,029,761,599 23,222,127 18,062 — Accordingly, Dr. Alessandro Riva was re-elected to serve as a Class I director.